{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.00","value":"0.0"},{"groupId":"OG001","spread":"0.00","value":"0.0"},{"groupId":"OG002","spread":"0.00","value":"0.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"4"}],"units":"Participants"}],"title":"C1 D1, PRE-DOSE"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"9190.29","value":"31985.7"},{"groupId":"OG001","spread":"10478.63","value":"50220.0"},{"groupId":"OG002","spread":"9736.00","value":"47283.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"6"}],"units":"Participants"}],"title":"C1 D1, END OF INFUSION"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"8256.97","value":"31333.3"},{"groupId":"OG001","spread":"11250.09","value":"48970.0"},{"groupId":"OG002","spread":"12637.25","value":"47300.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"6"}],"units":"Participants"}],"title":"C1 D1, 2 HOURS"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"5629.64","value":"23342.9"},{"groupId":"OG001","spread":"9689.77","value":"34950.0"},{"groupId":"OG002","spread":"10519.32","value":"37700.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"6"}],"units":"Participants"}],"title":"C1 D1, 24 HOURS"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"6065.01","value":"16672.5"},{"groupId":"OG001","spread":"8853.78","value":"22250.0"},{"groupId":"OG002","spread":"6100.41","value":"26950.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"6"}],"units":"Participants"}],"title":"C1 D4, ANYTIME SAMPLE"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4290.74","value":"12197.5"},{"groupId":"OG001","spread":"7106.24","value":"15358.0"},{"groupId":"OG002","spread":"8274.19","value":"18690.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"6"}],"units":"Participants"}],"title":"C1 D8, ANYTIME SAMPLE"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2982.95","value":"5920.0"},{"groupId":"OG001","spread":"3611.93","value":"5921.3"},{"groupId":"OG002","spread":"5024.85","value":"10561.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"6"}],"units":"Participants"}],"title":"C2 D1, PRE-DOSE"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"10166.40","value":"39028.6"},{"groupId":"OG001","spread":"13992.93","value":"50425.0"},{"groupId":"OG002","spread":"19478.63","value":"60320.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"5"}],"units":"Participants"}],"title":"C2 D1, END OF INFUSION"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"6636.79","value":"13463.3"},{"groupId":"OG001","spread":"8186.51","value":"14532.5"},{"groupId":"OG002","spread":"14219.43","value":"18190.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"3"}],"units":"Participants"}],"title":"C4 D1, PRE-DOSE"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"37026.66","value":"75333.3"},{"groupId":"OG001","spread":"16597.46","value":"55975.0"},{"groupId":"OG002","spread":"21672.33","value":"68500.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"3"}],"units":"Participants"}],"title":"C4 D1, END OF INFUSION"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2474.87","value":"14450.0"},{"groupId":"OG001","spread":"10349.14","value":"13576.7"},{"groupId":"OG002","spread":"4452.43","value":"15026.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"}],"units":"Participants"}],"title":"C6 D1, PRE-DOSE"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"6858.94","value":"45150.0"},{"groupId":"OG001","spread":"16740.77","value":"62666.7"},{"groupId":"OG002","spread":"15202.80","value":"62450.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"2"}],"units":"Participants"}],"title":"C6 D1, END OF INFUSION"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"141.42","value":"14300.0"},{"groupId":"OG001","spread":"14117.13","value":"23533.3"},{"groupId":"OG002","spread":"7099.35","value":"8980.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"2"}],"units":"Participants"}],"title":"C9 D1, PRE-DOSE"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"9828.78","value":"47250.0"},{"groupId":"OG001","spread":"16721.54","value":"62100.0"},{"groupId":"OG002","spread":"6929.65","value":"75700.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"2"}],"units":"Participants"}],"title":"C9 D1, END OF INFUSION"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3726.45","value":"8165.0"},{"groupId":"OG001","spread":"20718.23","value":"15850.0"},{"comment":"SD is not applicable as only a single participant was analyzed. Mean value presented here is the actual concentration for this single participant.","groupId":"OG002","spread":"NA","value":"15000.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"1"}],"units":"Participants"}],"title":"C12 D1, PRE-DOSE"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"14354.27","value":"43250.0"},{"groupId":"OG001","spread":"25031.58","value":"54400.0"},{"comment":"SD is not applicable as only a single participant was analyzed. Mean value presented here is the actual concentration for this single participant.","groupId":"OG002","spread":"NA","value":"53800.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"1"}],"units":"Participants"}],"title":"C12 D1, END OF INFUSION"},{"categories":[{"measurements":[{"comment":"SD is not applicable as only a single participant was analyzed. Mean value presented here is the actual concentration for this single participant.","groupId":"OG000","spread":"NA","value":"8180.0"},{"comment":"SD is not applicable as only a single participant was analyzed. Mean value presented here is the actual concentration for this single participant.","groupId":"OG001","spread":"NA","value":"34500.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"title":"C18 D1, PRE-DOSE"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"6119.81","value":"11052.0"},{"groupId":"OG001","spread":"11401.80","value":"8862.0"},{"groupId":"OG002","spread":"15040.13","value":"15643.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"3"}],"units":"Participants"}],"title":"EoT (up to ~ 281 weeks)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"6"}],"units":"Participants"}],"description":"Blood samples were collected for PK analysis of Belantamab mafodotin total antibody.","dispersionType":"Standard Deviation","groups":[{"description":"Participants with Relapsed/Refractory Multiple Myeloma (RRMM) received 1.9 milligram (mg)/kilogram (kg) of belantamab mafodotin intravenous (IV) infusion in combination with 8 mg feladilimab IV infusion, given 1 hour after belantamab mafodotin end of infusion (EOI), once every 3 weeks (Q3W).","id":"OG000","title":"1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab"},{"description":"Participants with RRMM received 2.5 mg/kg belantamab mafodotin IV infusion in combination with 8 mg feladilimab IV infusion, given 1 hour after belantamab mafodotin EOI Q3W.","id":"OG001","title":"2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab"},{"description":"Participants with RRMM received 2.5 mg/kg belantamab mafodotin IV infusion in combination with 24 mg feladilimab IV infusion, given 1 hour after belantamab mafodotin EOI Q3W.","id":"OG002","title":"2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab"}],"paramType":"MEAN","populationDescription":"PK population. Only those participants who were measured and analyzed (i.e., contributed data reported in the table) were included in the Overall Number of Participants Analyzed field. 'Number Analyzed' signifies participants evaluable for the specified timepoints. The \"0\" participants analyzed represents that data was not collected for analysis at that particular time point for the respective Arms/Groups.","reportingStatus":"POSTED","timeFrame":"Predose, EOI, 2 and 24 hours postdose on C1 D1, anytime sample at C1 D4, D8; Predose and EOI on D1 of C2, C4, C6, C9, C12; Predose on C18 D1; and at EoT (up to approximately 281 weeks.)","title":"DE Phase: Plasma Concentration of Belantamab Mafodotin Total Antibody","type":"SECONDARY","unitOfMeasure":"Nanogram/ millilitre (ng/mL)"}